CRISPR Therapeutics

NASDAQ:CRSPBiotech

Switzerland · Est. 2013

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

Clinical Trials↗

All sponsored trials (all statuses)

Pipeline

Pipeline Snapshot

By Phase

3 drugs in development

Phase 22

Phase 12

Preclinical1

By Therapeutic Area

top 3

Oncology

240%

Immunology

120%

Neurology

120%

R&D Momentum

50/100

Pipeline Velocity

15/100

Trial Completion Rate

20/100

Pipeline Concentration

28/100

Pipeline Freshness

78/100

Strategic Signals

↗Early-stage heavy pipeline may seek late-stage partners
↗Active in Oncology but thin pipeline — potential licensing opportunity

Activity

Recent Activity

Last 14 days

Sep 19, 2026

Recruiting

A Phase 1 Open-label, Multicenter, First-in-human, Ascending Dose Trial Evaluating the Safety and Tolerability of a Lipid Nanoparticle Formulation of CRISPR-Guide RNA-Cas9 Nuclease (CTX310) for In Vivo Editing of the Angiopoietin-like 3 (ANGPTL3) Gene in Participants With Refractory Dyslipidemias

Earlier

Aug 29, 2026TrialA Phase 1 Dose Evaluation Study of the Safety and Preliminary Efficacy of Anti-CD19 Allogeneic CRISPR-Cas9-Engineered T Cells (CTX112) in Adult Subjects With Refractory Autoimmune Disease

Aug 12, 2026TrialA Phase 1/2 Multicenter, First-in-human, Ascending Dose Trial Evaluating the Safety, Tolerability, and Efficacy of a Lipid Nanoparticle Formulation of CRISPR-Guide RNA-Cas9 Nuclease (CTX340) for In Vivo Editing of the Angiotensinogen (AGT) Gene in Participants With Hypertension

Jul 23, 2026TrialA Phase 1/2 Dose Evaluation Trial of the Safety and Preliminary Efficacy of Anti CD19 Allogeneic CRISPR-Cas9-Engineered T Cells (CTX112) in Adult Participants With Relapsed/Refractory Hematologic Autoimmune Disease

Mar 15, 2026TrialCLIMB-121 Extension: Exa-cel Follow-Up in SCD

Mar 13, 2026TrialCLIMB SCD-121: Exa-cel in Sickle Cell Disease

Mar 11, 2026TrialCLIMB THAL-111: Exa-cel in Beta-Thalassemia

Aug 13, 2024TrialA Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed/Refractory Hematologic Malignancies

3 more events

Mar 13, 2023TrialA Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors

Mar 10, 2023TrialA Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies

Jul 31, 2020TrialA Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory T or B Cell Malignancies (COBALT-LYM)